pharma · Relapsed or Refractory Multiple Myeloma (RRMM) · Relapsed and/or Refractory Multiple Myeloma
Celgene
Celgene Europe Limited
Celgene clinical programs — 17 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Summit, USA
- Employees
- 2,104
- Programs
- 45
- Drugs
- 91
- Patents
- 0
Celgene projects
17 ClinicalTrials.gov programs sponsored by Celgene.
Celgene has 17 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
ACE-536
Celgene Europe Limited
Beta-Thalassemia
1 trial -
AG-221-AML-005
Celgene Europe Limited
Acute Myeloid Leukemia (AML)
1 trial -
CA057-003
Celgene Europe Limited
Relapsed or Refractory Multiple Myeloma (RRMM)
1 trial -
CA057-1040
Celgene Europe Limited
Relapsed or Refractory Multiple Myeloma (RRMM)
1 trial -
CA058-002
Celgene Europe Limited
Relapsed and/or Refractory Multiple Myeloma
1 trial -
CA061-1011
Celgene Europe Limited
Lupus Nephritis, Systemic Lupus Erythematosus
1 trial -
CA073-1022
Celgene Europe Limited
Newly Diagnosed Advanced Stage Follicular Lymphoma
1 trial -
CC-220-MM-001
Celgene Europe Limited
Multiple Myeloma
1 trial -
CC-486-NSCL-001
Celgene Europe Limited
Second-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)
1 trial -
CC-92480-MM-001
Celgene Europe Limited
Relapsed and refractory multiple myeloma (RRMM)
1 trial -
CC-92480-MM-002
Celgene Europe Limited
Relapsed or refractory multiple myeloma (RRMM) and newly diagnosed MM (NDMM)
1 trial -
CC-99282-NHL-001
Celgene Europe Limited
Follicular B-cell non-Hodgkin's lymphoma, Primary central nervous system lymphoma, Marginal zone lymphoma, Diffuse large B-cell lymphoma, Mantle cell lymphoma
1 trial -
IM045-1018
Celgene Europe Limited
Multiple Sclerosis Spasticity
1 trial -
JCAR017
Celgene Europe Limited
Lymphoma, Non-Hodgkin
1 trial -
Lisocabtagene maraleucel
Celgene Europe Limited
Relapsed or refractory indolent B-cell Non-Hodgkin Lymphoma (NHL)
1 trial -
Pomalidomide
Celgene Europe Limited
Multiple Myeloma
1 trial -
idecabtagene vicleucel
Celgene Europe Limited
Relapsed and refractory multiple myeloma (RRMM), multiple myeloma (MM) with progression within 18 months of initial treatment/ or newly diagnosed multiple myeloma (NDMM) with suboptimal response post autologous stem cell transplant (ASCT) (Cohort 3 only)
1 trial
Frequently asked questions
How many clinical projects does Celgene have?
17 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.